Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating Treatment Factor X in People With Factor X Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent given, or for subjects aged 12-17 years, have given written assent and whose parent/guardian has given written informed consent~* At least 12 years of age at dtae of written informed consent~* Have hereditary severe or moderate FX deficiency~* Currently treated with Fresh Frozen Plasma FFP, Prothrombin Complex Concentrate PCC or factor IX/X concentrate~* Must have a minimum of one spontaneous or menorrhagic bleed in the last 12 months which required treatment of FFP, PCC or factor IX/X concentrate. Newly diagnosed subjects who present at the hospital with a bleed may be included~* Must have had at least 7 days, and ideally 10-14 days, since an infusion of either FFP, PCC or factor IX/X concentrate at Baseline Visit~* Females of child bearing potential must have a negative result on a HCG based pregnancy test. If they are or become sexually active, they must practise contraception by using a method of proven reliability for the duration of the study~Exclusion Criteria:~* Have a history of inhibitor development to FX or a positive result at the Screening Visit~* Bleeding at the appointment for the PK assessment~* Subjects who have thrombocytopenia~* Have clinically significant liver disease~* Known to have other coagulopathy or thrombophilia~* Have known or suspected hypersensitivity to the investigational medicinal product or its excipients~* Have abused chemicals or drugs within the past 12 months~* Have a history of unreliability or non-cooperation~* Participating or have taken part in another trial within the last 30 days, with the exception of BPL FX surgery study - Protocol Ten03. In such cases, subjects should have completed their End of Study Visit either before or on the day of Screening Visit for this study~* Female subjects who are pregnant or lactating~* Subjects planning greater than 4 weeks absence from the locality of the Investigational site, between the screening visit and the repeat PK assessment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human Coagulation FACTOR X (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).